Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XF0S | ISIN: US00972D1054 | Ticker-Symbol: AX9
Tradegate
27.06.25 | 17:08
3,112 Euro
-2,51 % -0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AKEBIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
AKEBIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,0823,13220:05
3,0823,13220:05

Aktuelle News zur AKEBIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
AKEBIA Aktie jetzt für 0€ handeln
13.06.Akebia Therapeutics, Inc. - 8-K, Current Report14
04.06.Akebia berichtet über gemischte Ergebnisse für Anämie-Medikament in globaler Studie19
04.06.Akebia Therapeutics, Inc.: Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology166CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease...
► Artikel lesen
04.06.H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating4
02.06.Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)94CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease...
► Artikel lesen
27.05.Akebia Therapeutics, Inc.: Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 20257
08.05.Akebia projects Vafseo rollout to double patient access by Q4 202511
08.05.Akebia Therapeutics, Inc. - 10-Q, Quarterly Report12
08.05.Akebia Therapeutics, Inc. - 8-K, Current Report3
07.05.Insights Ahead: Akebia Therapeutics' Quarterly Earnings8
01.05.Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)120CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease...
► Artikel lesen
01.05.Akebia Therapeutics, Inc.: Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights3
28.04.Leerink raises Akebia stock to outperform with $7 target6
04.04.Akebia stock holds Buy rating, $7.50 target from H.C. Wainwright7
03.04.Akebia Therapeutics gets EU positive recommendation for Xoanacyl2
03.04.Akebia Therapeutics: CHMP Adopts Positive Opinion On XOANACYL2
03.04.Akebia Therapeutics, Inc.: Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa176CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease...
► Artikel lesen
02.04.Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)110CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease...
► Artikel lesen
01.04.Jefferies sets Akebia Therapeutics stock at Buy, $6 price target6
26.03.Piper Sandler maintains Akebia stock with $6 price target7
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1